April 14, 2021 -- InvestorsHub NewsWire -- via Facts About CBD - Ward Sport



Pao Group Inc. (OTCMKTS:PAOG)
 has announced that it expects revenue expansion this year from CBD neutraceuticals. The company published an online and multimedia presentation showing its CBD nutraceutical development expansion plans. Most importantly, the presentation includes its strategy engagements with Puration Inc. (OTCMKTS:PURA), Alkme Holdings Inc. (OTCMKTS:ALKM), and North American Cannabis Holdings Inc. (OTCMKTS:USMJ).


Pao Group acquired RespRx in 2020

Last year, the company completed the acquisition of RespRx, a cannabis medication currently under development for the treatment of Chronic Obstructive Pulmonary Disorder derived through a patented marijuana extraction method. According to WHO, around 65 million globally have moderate to severe COPD, with around three million deaths reported each year. COPD treatment market is estimated to be around $5 billion in the US and $11 billion globally.

Notably, GW Pharmaceuticals has set the base for cannabis treatment and recently was valued at $7.2 billion. The patented extraction method inventor Frederic Ferri said that doctors researching their feedback have given feedback regarding the feedback’s superiority compared to those of GW Pharmaceuticals.

Pao Group recently entered an engagement with Veristat Inc. to assist in advancing its novel CBD extract for COPD treatment towards an IND with the  US FDA. The company recognizes and acknowledges that pharmaceutical development will be a capital intensive and long-term undertaking. As a result, Pao Group is pursuing complementary business initiatives that can generate revenue in the near term and contribute to funding the RespRx development in the long term.

Pao Group expanding nutraceutical development

Besides efforts to develop COPD treatment, the company also announced that it has engaged Puerto Rico Consortium for Clinical Investigation to help it develop novel CBD extract into nutraceutical products for the care of individuals experiencing issues related to COPD. Pao Group management is confident that CBD extraction knowledge base and experience can help pursue the development of more neutraceuticals.
As a result, doing so will expand the company’s overall near-term revenue potential. The company expects revenue this year from neutraceuticals following the recent sales agreement with Puration. The company expects revenue of $50,000 each quarter.

Source - https://factsaboutcbd.org/pao-group-inc-otcmktspaog-expanding-its-neutraceutical-revenue-streams-4319

 

PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more PAO (PK) Charts.
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more PAO (PK) Charts.